Department of Internal Medicine, Institute of Medicine, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Department of Internal Medicine, Sahlgrenska University Hospital, University of Gothenburg, Blå stråket 5, SE-413 45, Göteborg, Sweden.
BMC Neurol. 2019 Jul 25;19(1):177. doi: 10.1186/s12883-019-1406-3.
Insulin resistance (IR) in relation to diabetes is a risk factor for ischemic stroke (IS), whereas less is known about non-diabetic IR and outcome after IS.
In non-diabetic IS (n = 441) and controls (n = 560) from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS), IR was investigated in relation to IS severity and functional outcome. IR was evaluated acutely and after 3 months using the Homeostasis model assessment of IR (HOMA-IR). Stroke severity was assessed by the National Institutes of Health Stroke Scale (NIHSS). Functional outcome was evaluated using the modified Rankin Scale (mRS) after 3 months, 2 and 7 years. Associations were evaluated by logistic regression.
Higher acute and 3-month HOMA-IR was observed in IS compared to the controls (both p < 0.001) and in severe compared to mild IS (both p < 0.05). High acute HOMA-IR was associated with poor outcome (mRS 3-6) after 3 months and 7 years [crude Odds ratios (ORs), 95% confidence intervals (CIs) 1.50, 1.07-2.11 and 1.59, 1.11-2.30, respectively], but not after 2 years. These associations lost significance after adjustment for all covariates including initial stroke severity. In the largest IS subtype (cryptogenic stroke), acute HOMA-IR was associated with poor outcome after 2 years also after adjustment for age and stroke severity (OR 2.86, 95% CI 1.01-8.12).
In non-diabetic IS patients, HOMA-IR was elevated and related to stroke severity, but after adjustment for IS severity, the associations between HOMR-IR and poor outcome lost significance. This could suggest that elevated IR mostly is a part of the acute IS morbidity. However, in the subgroup of cryptogenic stroke, the associations with poor outcome withstood correction for stroke severity.
与糖尿病相关的胰岛素抵抗(IR)是缺血性中风(IS)的一个危险因素,而对于非糖尿病性 IR 及其 IS 后的结果知之甚少。
在非糖尿病性 IS(n=441)和对照者(n=560)中,来自萨赫勒格斯纳学院缺血性中风研究(SAHLSIS),研究了 IR 与 IS 严重程度和功能结果的关系。使用稳态模型评估的胰岛素抵抗(HOMA-IR)在急性期和 3 个月时评估 IR。中风严重程度采用国立卫生研究院中风量表(NIHSS)评估。3 个月、2 年和 7 年后采用改良 Rankin 量表(mRS)评估功能结局。通过逻辑回归评估相关性。
与对照组相比(均 p<0.001),IS 患者的急性期和 3 个月时 HOMA-IR 更高,与轻度 IS 相比,严重 IS 患者的 HOMA-IR 更高(均 p<0.05)。急性期 HOMA-IR 与 3 个月和 7 年后的不良结局(mRS 3-6)相关(未经调整的优势比[ORs],95%置信区间[CI]分别为 1.50、1.07-2.11 和 1.59、1.11-2.30),但 2 年后则不然。在调整了所有协变量(包括初始中风严重程度)后,这些相关性失去了意义。在最大的 IS 亚型(隐源性中风)中,即使在校正了年龄和中风严重程度后,急性期 HOMA-IR 也与 2 年后的不良结局相关(OR 2.86,95%CI 1.01-8.12)。
在非糖尿病性 IS 患者中,HOMA-IR 升高且与中风严重程度相关,但在校正 IS 严重程度后,HOMA-IR 与不良结局之间的相关性失去了意义。这可能表明,升高的 IR 主要是急性 IS 发病机制的一部分。然而,在隐源性中风亚组中,与不良结局的相关性在纠正中风严重程度后仍然存在。